Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

by GlobeNewswire

Oct 09, 2024 6:38 pm

- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months -

- Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events -

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

Already have an account? Log in here

Related Articles